129 related articles for article (PubMed ID: 1385802)
21. Handling of 99mTc-MAG3 in the kidney.
Müller-Suur C; Müller-Suur R
Contrib Nephrol; 1990; 79():17-20. PubMed ID: 2146082
[No Abstract] [Full Text] [Related]
22. Pharmacokinetics of technetium-99m-MAG3 in humans.
Bubeck B; Brandau W; Weber E; Kälble T; Parekh N; Georgi P
J Nucl Med; 1990 Aug; 31(8):1285-93. PubMed ID: 2143528
[TBL] [Abstract][Full Text] [Related]
23. Radiation dosimetry for technetium-99m-MAG3, technetium-99m-DTPA, and iodine-131-OIH based on human biodistribution studies.
Stabin M; Taylor A; Eshima D; Wooter W
J Nucl Med; 1992 Jan; 33(1):33-40. PubMed ID: 1530968
[TBL] [Abstract][Full Text] [Related]
24. Clinical evaluation of technetium-99m-L,L-ethylenedicysteine in patients with chronic renal failure.
Prvulovich EM; Bomanji JB; Waddington WA; Rudrasingham P; Verbruggen AM; Ell PJ
J Nucl Med; 1997 May; 38(5):809-14. PubMed ID: 9170451
[TBL] [Abstract][Full Text] [Related]
25. Measurements of 99mTc-MAG3 uptake in renal transplant recipients.
Oei HY; Surachno S; Wilmink JM; van der Schoot JB
Contrib Nephrol; 1990; 79():113-7. PubMed ID: 2146080
[No Abstract] [Full Text] [Related]
26. Preparation of the renal function and imaging agent 99mTc-MAG3 starting from S-unprotected mercaptoacetyltriglycine.
Noll B; Johannsen B; May K; Spies H
Int J Rad Appl Instrum A; 1992 Jul; 43(7):899-901. PubMed ID: 1321100
[TBL] [Abstract][Full Text] [Related]
27. Preliminary results comparing the extraction efficiencies of 131I-OIH and 99mTc-MAG3 in rat models of ischemia, renal artery stenosis, and ciclosporin toxicity.
Taylor A; Greene J; Eshima D; Dillehay D
Contrib Nephrol; 1990; 79():21-3. PubMed ID: 2146084
[No Abstract] [Full Text] [Related]
28. Evaluation of technetium-99m-L,L-EC in renal transplant recipients: a comparative study with technetium-99m-MAG3 and iodine-125-OIH.
Stoffel M; Jamar F; Van Nerom C; Verbruggen A; Mourad M; Leners N; Squifflet JP; Beckers C
J Nucl Med; 1994 Dec; 35(12):1951-8. PubMed ID: 7989976
[TBL] [Abstract][Full Text] [Related]
29. Renal parenchymal transit time of 99mTc-MAG3 from factor analysis and from region-of-interest selection in hydronephrosis.
Russell CD; Yester MV; Dubovsky EV
Contrib Nephrol; 1990; 79():68-71. PubMed ID: 2146088
[No Abstract] [Full Text] [Related]
30. Prospective validation of a single sample technique to determine technetium-99m-MAG3 clearance.
Taylor A; Corrigan P; Eshima D; Folks R
J Nucl Med; 1992 Sep; 33(9):1620-2. PubMed ID: 1387682
[TBL] [Abstract][Full Text] [Related]
31. 188Re- and 99mTc-MAG3 as prosthetic groups for labeling amines and peptides: approaches with pre- and postconjugate labeling.
Guhlke S; Schaffland A; Zamora PO; Sartor J; Diekmann D; Bender H; Knapp FF; Biersack HJ
Nucl Med Biol; 1998 Oct; 25(7):621-31. PubMed ID: 9804043
[TBL] [Abstract][Full Text] [Related]
32. 99mTc renal tubular function agents: current status.
Eshima D; Fritzberg AR; Taylor A
Semin Nucl Med; 1990 Jan; 20(1):28-40. PubMed ID: 2136959
[TBL] [Abstract][Full Text] [Related]
33. [The radiolabeling property of oligonucleotide with 99mTc using NHS-MAG3 as a chelator].
Zhang C; Tan TZ; Kuang AR; Li YC; Zheng JG; Pan WM
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Mar; 35(2):169-71. PubMed ID: 15071906
[TBL] [Abstract][Full Text] [Related]
34. Technetium-99m-MAG3 clearance as a parameter of effective renal plasma flow in patients with proteinuria and lowered serum albumin levels.
Kengen RA; Meijer S; Beekhuis H; Piers DA
J Nucl Med; 1991 Sep; 32(9):1709-12. PubMed ID: 1831839
[TBL] [Abstract][Full Text] [Related]
35. Renal function studies using 99mTc-MAG3: pharmacokinetics and slope clearance determination.
Bubeck B; Brandau W; Weber E; Pomer S; Georgi P; zum Winkel K
Contrib Nephrol; 1990; 79():72-3. PubMed ID: 2146089
[No Abstract] [Full Text] [Related]
36. Comparative study of the kinetics of the renal tracers 99Tcm-MAG3 and 131I-hippuran.
Pavía J; Ros D; Piera C; Pavía A; Bassa P; Giralt E; Setoain J
Nucl Med Commun; 1991 Jun; 12(6):529-37. PubMed ID: 1830943
[TBL] [Abstract][Full Text] [Related]
37. Dicarboxylate diamide dimercaptide (N2S2) technetium-99m complexes: synthesis and biological evaluation as potential renal radiopharmaceuticals.
Canney DJ; Billings J; Francesconi LC; Guo YZ; Haggerty BS; Rheingold AL; Kung HF
J Med Chem; 1993 Apr; 36(8):1032-40. PubMed ID: 8478903
[TBL] [Abstract][Full Text] [Related]
38. Using the "integral spleen" method of radiorenogram analysis and a baboon model to compare the diagnostic usefulness of technetium-99m-diethylenetriamine pentaacetic acid to that of various technetium-99m-mercaptoacetyltriglycene formulations and iodine-123-hippuran.
Dormehl IC; Van Wyk A; Pilloy W; Maree M; Knoesen O; De Winter R; Jacobs L; Hoppe HC
Am J Physiol Imaging; 1989; 4(1):23-7. PubMed ID: 2522307
[TBL] [Abstract][Full Text] [Related]
39. Preliminary results comparing OIH, 99mTc-MAG3 and iothalamate in a rat model of renal ischemia.
Eshima D; Greene J; Taylor A
Contrib Nephrol; 1990; 79():24-7. PubMed ID: 2146085
[No Abstract] [Full Text] [Related]
40. Effect of protein binding on renal extraction of 131I-OIH and 99mTc-labeled tubular agents.
Eshima D; Eshima L; Hansen L; Lipowska M; Marzilli LG; Taylor A
J Nucl Med; 2000 Dec; 41(12):2077-82. PubMed ID: 11138695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
